334 related articles for article (PubMed ID: 12891542)
21. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Wolfe F; Michaud K; Burke TA; Zhao SZ
J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
[TBL] [Abstract][Full Text] [Related]
22. Effect of cyclooxygenase-2 inhibitors on blood pressure.
Johnson DL; Hisel TM; Phillips BB
Ann Pharmacother; 2003 Mar; 37(3):442-6. PubMed ID: 12639178
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic advances with coxibs: few certainties and a lot of doubts].
Jouzeau JY; Daouphars M; Netter P
Therapie; 2004; 59(2):207-11. PubMed ID: 15359614
[No Abstract] [Full Text] [Related]
24. [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Nakamura H
Nihon Yakurigaku Zasshi; 2001 Sep; 118(3):219-30. PubMed ID: 11577463
[TBL] [Abstract][Full Text] [Related]
25. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
Howes LG; Krum H
Drug Saf; 2002; 25(12):829-35. PubMed ID: 12241124
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Patrono C; Patrignani P; García Rodríguez LA
J Clin Invest; 2001 Jul; 108(1):7-13. PubMed ID: 11435450
[No Abstract] [Full Text] [Related]
27. Risk of cardiovascular events associated with selective COX-2 inhibitors.
Mukherjee D; Nissen SE; Topol EJ
JAMA; 2001 Aug 22-29; 286(8):954-9. PubMed ID: 11509060
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
30. COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?
Simon LS
Gastroenterol Clin North Am; 2001 Dec; 30(4):1011-25, viii. PubMed ID: 11764530
[TBL] [Abstract][Full Text] [Related]
31. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
32. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
33. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy.
Bouée S; Charlemagne A; Fagnani F; Le Jeunne P; Sermet C; Naudin F; Lancry PJ
Joint Bone Spine; 2004 May; 71(3):214-20. PubMed ID: 15182793
[TBL] [Abstract][Full Text] [Related]
34. [Clinical use of COX-2 inhibitors].
Ristić GG; Stefanović DZ
Vojnosanit Pregl; 2001; 58(3):283-95. PubMed ID: 11548555
[No Abstract] [Full Text] [Related]
35. Efficacy of cyclooxygenase-2-specific inhibitors.
Cannon GW; Breedveld FC
Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
[TBL] [Abstract][Full Text] [Related]
36. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582
[No Abstract] [Full Text] [Related]
37. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs.
Perazella MA; Tray K
Am J Med; 2001 Jul; 111(1):64-7. PubMed ID: 11448662
[No Abstract] [Full Text] [Related]
38. Interaction of rofecoxib and celecoxib with warfarin.
Schaefer MG; Plowman BK; Morreale AP; Egan M
Am J Health Syst Pharm; 2003 Jul; 60(13):1319-23. PubMed ID: 12901032
[TBL] [Abstract][Full Text] [Related]
39. Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?
Crofford LJ
Curr Opin Rheumatol; 2002 May; 14(3):225-30. PubMed ID: 11981317
[TBL] [Abstract][Full Text] [Related]
40. [New anti-inflammatory analgetics--are they needed?].
Paakkari I
Duodecim; 1999; 115(20):2217-24. PubMed ID: 11973925
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
